Catalyst
Slingshot members are tracking this event:
Tesaro (TSRO) to Enroll Phase 3 PRIMA Trial Evaluating Niraparib in 1L Ovarian Cancer Throughout 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TSRO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 11, 2017
Occurred Source:
http://ir.tesarobio.com/releasedetail.cfm?ReleaseID=1025986
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Prima, Niraparib, 1l Ovarian Cancer
